share_log

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax制药 | 8-K：VIRPAX PHARMICALS公布2024年第二季度业绩和近期进展
美股SEC公告 ·  2024/08/13 04:37

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals announced its Q2 2024 financial results, reporting an operating loss of $3.5M compared to $3.1M in Q2 2023. General and administrative expenses decreased to $1.5M from $1.9M, while R&D expenses increased to $2.0M from $1.3M YoY. The company ended the quarter with $1.9M in cash.The company reported positive results from its pharmacokinetics and safety study for Probudur, its lead pain relief asset, in a Swine Model pilot study. The study demonstrated well-tolerated results and a long-term, slow-release profile. Additionally, Virpax secured $2.8M through warrant exercises in July 2024 and regained Nasdaq minimum bid price compliance.In other developments, Virpax closed a $2.5M secured loan to settle litigation, subsequently repaid through warrant proceeds. The company's board was reorganized and reduced to seven members. The company also completed a $2.25M public offering in May 2024, issuing shares and warrants at $1.35 per unit.
Virpax Pharmaceuticals announced its Q2 2024 financial results, reporting an operating loss of $3.5M compared to $3.1M in Q2 2023. General and administrative expenses decreased to $1.5M from $1.9M, while R&D expenses increased to $2.0M from $1.3M YoY. The company ended the quarter with $1.9M in cash.The company reported positive results from its pharmacokinetics and safety study for Probudur, its lead pain relief asset, in a Swine Model pilot study. The study demonstrated well-tolerated results and a long-term, slow-release profile. Additionally, Virpax secured $2.8M through warrant exercises in July 2024 and regained Nasdaq minimum bid price compliance.In other developments, Virpax closed a $2.5M secured loan to settle litigation, subsequently repaid through warrant proceeds. The company's board was reorganized and reduced to seven members. The company also completed a $2.25M public offering in May 2024, issuing shares and warrants at $1.35 per unit.
Virpax制药公司发布了2024年第二季度的财务结果，报告的经营亏损为350万美元，比2023年第二季度的310万美元有所增加。一般和管理费用从190万美元减少至150万美元，而研发费用则同比增加至200万美元，从130万美元提高。公司在季度末现金余额为190万美元。该公司在其主要止痛资产Probudur的药代动力学和安全性研究中获得了积极结果，采用的是猪模型的试点研究。该研究显示了良好的耐受性和长期的缓释特性。此外，Virpax在2024年7月通过行使认股权证获得了280万美元，并重新符合纳斯达克最低买盘价格的合规性。在其他方面，Virpax关闭了一笔250万美元的担保贷款以解决诉讼，随后通过认股权证收益进行了偿还。公司的董事会进行了重组，减少至七名成员。该公司还在2024年5月完成了225万美元的公开发行，以每单位1.35美元的价格发行股票和认股权证。
Virpax制药公司发布了2024年第二季度的财务结果，报告的经营亏损为350万美元，比2023年第二季度的310万美元有所增加。一般和管理费用从190万美元减少至150万美元，而研发费用则同比增加至200万美元，从130万美元提高。公司在季度末现金余额为190万美元。该公司在其主要止痛资产Probudur的药代动力学和安全性研究中获得了积极结果，采用的是猪模型的试点研究。该研究显示了良好的耐受性和长期的缓释特性。此外，Virpax在2024年7月通过行使认股权证获得了280万美元，并重新符合纳斯达克最低买盘价格的合规性。在其他方面，Virpax关闭了一笔250万美元的担保贷款以解决诉讼，随后通过认股权证收益进行了偿还。公司的董事会进行了重组，减少至七名成员。该公司还在2024年5月完成了225万美元的公开发行，以每单位1.35美元的价格发行股票和认股权证。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 100.490
    Citius Pharmaceuticals
    CTXR
    -- 2.1709
    bluebird bio
    BLUE
    -- 5.250
    NLS Pharmaceutics
    NLSP
    -- 1.4896
    莱斯康制药
    LXRX
    -- 0.639
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日